Randox Presents Future of Diagnostic Technology
|
By LabMedica International staff writers Posted on 21 May 2023 |

Randox Laboratories (Crumlin, UK) is showcasing its extensive range of innovative products that are revolutionizing healthcare at the 2023 EuroMedLab Congress.
At EuroMedLab Rome 2023, Randox is introducing the new Acusera third-party controls designed for comprehensive test menu consolidation in laboratory internal quality control. These third-party controls are "true," meaning they are not biased towards or optimized for any specific reagent, method, or instrument, and hence offer an objective assessment of performance. Notably, several Acusera controls are produced using 100% human materials, mimicking a patient sample's behavior and thus providing an accurate reflection of the test system's performance.
Also on display at the industry event is Randox's Vivalytic, an all in one molecular diagnostic solution. This compact benchtop platform consolidates the complete molecular workflow, including extraction, PCR amplification, and detection. The unique multiplex Biochip Technology from Randox powers the Vivalytic, yielding multiple results from a single patient sample. The biochip detection system based on a chemiluminescent signal, which is the emission of light without heat from a chemical reaction. Each biochip is pre-engineered with spatially distinct testing regions (DTRs), each representing an individual test. Each DTR can be occupied with oligonucleotides specific to a pathogen or target of interest, allowing the high-plex capabilities of the Biochip Technology to eliminate the need for running multiple, time-consuming, and sample-intensive assays.
Randox is holding live demonstrations of ACUSERA 24•7 Interlaboratory Data Management which provides instant access to an unrivalled range of features including QC multi-rules, interactive charts, live peer group data, automatic calculation of Measurement Uncertainty & Sigma Metrics & a unique dashboard interface, all designed to speed up the review process and provide at-a-glance performance assessment. Randox is also demonstrating RIQAS (Randox International Quality Assessment Scheme which is used by more than 55,000 laboratory participants in 134 countries and accredited to ISO 17043. As a result, Randox has RIQAS users on every continent who are registered for one or more of its 36 flexible EQA programs, utilizing the available data to ensure the quality and reliability of their results.
ACUSERA 24•7 Interlaboratory Data Management, a feature-rich platform offering QC multi-rules, interactive charts, live peer group data, automatic calculation of Measurement Uncertainty & Sigma Metrics & a unique dashboard interface. All these features are designed to expedite the review process and provide at-a-glance performance assessment. Further, Randox is also demonstrating its RIQAS (Randox International Quality Assessment Scheme), an ISO 17043-accredited scheme employed by over 55,000 lab participants across 134 countries. Thanks to its global footprint, Randox has RIQAS users in every continent who are registered for one or more of its 36 flexible EQA programs, thereby leveraging available data to assure the quality and dependability of their results.
Related Links:
Randox Laboratories
Latest EUROMEDLAB 2023 News
- DIESSE Diagnostica Unveils CHORUS EVO Immunochemistry Analyzer
- LGC Clinical Diagnostics Demonstrates Lab Solutions and Processes to Enhance QC Efficiencies
- LumiraDx Demonstrates Fast, High Performance, Portable POC Diagnostic Solution
- Thermo Fisher Presents Latest Solutions in Laboratory Equipment and Technology
- Beckman Coulter Unveils New DxI 9000 Access Immunoassay Analyzer
- STAGO sthemO and sthemE Product Ranges Make World Premiere
- Sansure Biotech Demonstrates iPonatic III Portable Molecular Workstation
- Greiner Bio-One Presents Complete Concept of Digitalized Sample Collection Process
- BioPerfectus Showcases SAW-48 Automated Nucleic Acid Workstation
- Menarini Introduces PRIME MDx All-in-One Molecular Diagnostics Solution
- Werfen Showcases Latest Innovations in Specialized Diagnostics
- Binding Site Showcases Optilite System for Special Protein Testing
- Sebia Presents Innovative Solutions for Screening and Diagnostics
- DiaSorin Showcases Latest Assays and Reagents for In-Vitro Diagnostics
- Abbott Introduces GLP Systems Track Laboratory Automation Solution
- QuidelOrtho Highlights Innovative Point-of-Care Diagnostic Solutions
Channels
Clinical Chemistry
view channelNew Blood Test Index Offers Earlier Detection of Liver Scarring
Metabolic fatty liver disease is highly prevalent and often silent, yet it can progress to fibrosis, cirrhosis, and liver failure. Current first-line blood test scores frequently return indeterminate results,... Read more
Electronic Nose Smells Early Signs of Ovarian Cancer in Blood
Ovarian cancer is often diagnosed at a late stage because its symptoms are vague and resemble those of more common conditions. Unlike breast cancer, there is currently no reliable screening method, and... Read moreMolecular Diagnostics
view channel
Simple One-Hour Saliva Test Detects Common Cancers
Early detection is critical for improving cancer outcomes, yet many diagnostic tests rely on invasive procedures such as blood draws or biopsies. Researchers are exploring simpler approaches that could... Read more
Blood Test Could Help Guide Treatment Decisions in Germ Cell Tumors
Chemotherapy is often highly effective for germ cell tumors, but in a subset of patients, the disease does not respond well to standard treatment. For these individuals, doctors may consider high-dose... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Rapid Sequencing Could Transform Tuberculosis Care
Tuberculosis remains the world’s leading cause of death from a single infectious agent, responsible for more than one million deaths each year. Diagnosing and monitoring the disease can be slow because... Read more
Blood-Based Viral Signature Identified in Crohn’s Disease
Crohn’s disease is a chronic inflammatory intestinal disorder affecting approximately 0.4% of the European population, with symptoms and progression that vary widely. Although viral components of the microbiome... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more








